Chuck Norris sues gadolinium manufacturers, claims wife was poisoned

Melissa Rohman | | Health Imaging | Cardiac Imaging

Acclaimed action star Chuck Norris filed a lawsuit Wednesday, Nov. 1, alleging gadolinium from MRI imaging scans has poisoned his wife, Gena, and is seeking more than $10 million in damages to cover her medical expenses. The suit names several manufacturers of gadolinium contrast agents.

According to a recent article from The Washington Post, the lawsuit states that Norris' wife has been left feeling week and tired with "debilitating bouts of pain and a burning sensation" due to gadolinium usage to improve clarity of her MRI scans. 

“One of the problems is this is a very misdiagnosed and underdiagnosed condition,” said Todd Walburg, an attorney for the Norris family. 

For more information, see the orginal article here.  

Chuck Norris sues over MRI chemical he says poisoned wife

""
Melissa Rohman

A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.

Related Content

FDA clears AI screening tool for cardiac amyloidosis
Global shortage of nuclear imaging isotopes may be over
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
FDA clears AI tool that flags signs of heart disease in chest CT scans
AI-enabled plaque assessments help cardiologists ID high-risk CAD patients
Abbott CGM sensors can now be worn during common imaging procedures

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup